Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Clover Biopharmaceuticals, Ltd.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Bror Morein

Novavax, Inc.

Clover Biopharmaceuticals is a global commercial-stage biotechnology company that develops innovative vaccines. Self-described to be committed to improving health worldwide.

Clover Biopharmaceuticals

Clover Biopharmaceuticals | 7,293 followers on LinkedIn. Unleashing the power of innovative vaccines to save lives and improve health around the world | Founded in 2007, we are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing, and commercial capabilities as well as strong partnerships with organizations globally, we have developed a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. As we focus on delivering vaccines for a healthier world, we remain steadfast in our dedication to both scientific innovation and equitable access.

Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals

Jeff Farrow

Senior Director Clinical Operation at Clover Biopharmaceuticals

Aurore Dujardin

Founder， Chairman of the Board of Clover Biopharmaceuticals

Peng Liang

Building Around Talent

Oscar Shen

Attend Europe’s Largest Vaccine R&D Conference！ ☘️☘️☘️ WE ARE ATTENDING AND PRESENTING! ☘️☘️☘️ 📍WORLD VACCINE CONGRESS MEET YOU THERE! #WVC #CLOVER #Vaccine #RSV

Metric
Company Name	Clover Biopharmaceuticals, Ltd.	Moderna, Inc.	Novavax, Inc.
Symbol	2.20K	MRNA	NVAX
MSH ID	COM:CLOVERBIOPHARMA	COM:MODERNATX	COM:NOVAVAX
Market	STOCKS	STOCKS	STOCKS
Sector	Healthcare	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology
Country	CN	US	US
Stage	Post-IPO Equity
Employee Count	387	5.60K	1.54K
Website	cloverbiopharma.com	modernatx.com	novavax.com
LinkedIn	cloverbiopharmaceuticals		novavax
Founders

Metric
Market Cap	53.38M	45.01B	1.68B
Enterprise Value
Monthly Web Traffic	3.49K
Web Traffic Growth	0.41
Valuation
Raised Capital	36.90M

Metric
Revenue	5.40M	6.75B	983.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-230.14M	2.06B	704.24M
EBITDA	-354.93M	-3.21B	-373.80M
Operating Income	-358.92M	-4.24B	-415.03M
Net Income	-19.06M	-4.71B	-545.06M
EPS	-0.02	-12.34	-5.41
Diluted EPS	-0.02	-12.34	-5.41
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-15.46	0.32	0.60
Operating Profit Margin	-34.22	-0.62	-0.35
EBITDA Margin	-65.74	-0.48	-0.38
Net Profit Margin	-3.53	-0.69	-0.36
Return on Equity	2.08	-0.30	0.72
Return on Assets	-0.07	-0.26	-0.16
Return on Capital Employed	14.86	-0.28	-0.43

2197

COM:CLOVERBIOPHARMA

Clover Biopharmaceuticals

Last Close

0.28

25/11 07:31

Market Cap

415.27M

Beta: -

Volume Today

313K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.17	-10.50	-0.70
P/B Ratio	-0.64	2.71	-0.56
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.95K	12.39	3.54
EV Multiple	-0.25	-5.48	-1.84

Metric
Days Sales Outstanding		74.67	55.36
Days Payables Outstanding		31.73	100.39
Days Inventory Outstanding	534.63	42.12	45.07
Operating Cycle	1.07K	73.31	177.58
Cash Conversion Cycle	1.03K	43.23	34.23
Asset Turnover	0.02	0.37	0.61

Metric
Operating Cash Flow		-3.12B	-717.56M
Free Cash Flow		-3.83B	-776.36M
Cash Flow to Debt	-1.29	-2.28	0.08
Operating Cash Flow/Sales	-10.96	-0.46	0.02
Free Cash Flow Yield	-3.59	-0.07	-1.65

Metric
Cash & Equivalents	101.22M	2.91B	578.93M
Accounts Receivable		493M	-274.44M
Inventory	95.87M	202M	41.70M
Goodwill		52M	127.45M
Debt to Capitalization	0.94	0.10	-0.25
Debt to Assets	0.08	0.07	0.13
Current Ratio	1.55	2.46	0.69
Quick Ratio	0.55	3.92	1.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03	0.12
R&D to Revenue	0.51	1.02
SG&A to Revenue